Literature DB >> 15006391

Structure-activity relationships of a novel class of endothelin receptor selective antagonists; 6-carboxy-2-isopropylamino-5,7-diarylcyclopenteno[1,2-b]pyridines.

Hirobumi Takahashi1, Norikazu Ohtake, Toshihiro Sakamoto, Tomoharu Iino, Nobuhiko Kawanishi, Masayuki Nakamura, Takashi Yoshizumi, Kenji Niiyama, Satoshi Ozaki, Hiromasa Okada, Akiko Kano, Hiroyuki Takahashi, Yasuyuki Ishii, Megumu Okada, Michiyasu Saito, Yoshio Sawazaki, Takashi Hayama, Masaru Nishikibe.   

Abstract

The synthesis and structure-activity relationships of 6-carboxy-2-isopropylamino-5,7-diarylcyclopenteno[1,2-b]pyridine class of ET(A) receptor selective antagonists were described. These derivatives were prepared from the optically active key intermediates (3, 4, 10, and 13). Optimization of the substituent at the 2-position of the bottom 4-methoxyphenyl ring of the lead compound 1 led to identification of 2-hydroxy-1-methylethoxy (2g and h), hydroxyalkyl (2i, m, and p), 3-methoxy-2-methylpropyl (2t and u), N-acetyl-N-methylaminomethyl (2v), and 2-(dimethylcarbamoyl)propyl (2w) derivatives that showed greater than 1000-fold selectivity for the ET(A) receptor over the ET(B) receptor with excellent binding affinity (IC(50)<0.10 nM). Further screening of these compounds by assessing the plasma exposures at 1 h, 4 h, and 8 h after oral administration (3 or 10 mg/kg) in rats led to identification of the hydroxymethyl (2i) and 3-methoxy-2-methylpropyl (2u) derivatives exhibiting good oral bioavailability in rats.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15006391     DOI: 10.1016/j.bmcl.2004.01.008

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  1 in total

1.  Discovery of Dual ETA/ETB Receptor Antagonists from Traditional Chinese Herbs through in Silico and in Vitro Screening.

Authors:  Xing Wang; Yuxin Zhang; Qing Liu; Zhixin Ai; Yanling Zhang; Yuhong Xiang; Yanjiang Qiao
Journal:  Int J Mol Sci       Date:  2016-03-16       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.